Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Janux Therapeutics, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Pharmaceutical Preparations
Prev close 16.46 · gapped above the open, never looked back. High/low 17.31 at 7:15 am ET, 16.46 at 3:45 pm ET.
197 institutional managers report a position in Janux Therapeutics, Inc. worth $940.7M between them, filed on form 13F for the quarter ending 2026-06-30. 22 of them hold 80% of it, the largest being RA Capital Management, LLC at 18.27%.
172 more managers in the register
22 managers hold 80% of the $940.7M institutional base. The other 175 hold the rest.
Positions as filed with the SEC for the quarter ended Jun 30. A 13F is due 45 days after the quarter closes, so this register is 78 days old and does not move with the price above it.
via RA Capital Management, LLC, TCG Crossover Management, LLC, Woodline Partners LP +3 more · 18.27% of JANX, 17.47% of TYRA
via RA Capital Management, LLC, Alyeska Investment Group, L.P., ADAR1 Capital Management, LLC · 18.27% of JANX, 43.81% of ABOS
via RA Capital Management, LLC, Wellington Management Group LLP · 18.27% of JANX, 57.14% of ACRV
via RA Capital Management, LLC, Nantahala Capital Management, LLC, Alyeska Investment Group, L.P. +2 more · 18.27% of JANX, 44.47% of ARTV
via RA Capital Management, LLC, Squarepoint Ops LLC, Alyeska Investment Group, L.P. +1 more · 18.27% of JANX, 21.80% of HOWL
via RA Capital Management, LLC, ADAR1 Capital Management, LLC, Woodline Partners LP +1 more · 18.27% of JANX, 20.04% of CLYM
Managers holding a meaningful stake in JANX also hold this much of the other company’s institutional base. Managers who hold most of the companies we cover are excluded, because their overlap says nothing about this one in particular. This is how the two are held, not evidence that one moves the other.
JANX (Janux Therapeutics, Inc.) has 0 disclosed suppliers and 1 disclosed customers, strongest disclosure first.
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.
Largest move on the map today: MRK −0.16%, in healthcare.